Article
In silico approaches for drug repurposing in oncology: protocol for a scoping review of existing evidence
Registro en:
CAVALCANTE, Bruno Raphael Ribeiro et al. In silico approaches for drug repurposing in oncology: protocol for a scoping review of existing evidence. Plos One, v. 7, n. 17, p. 1-9, 2022.
1932-6203
10.1371/journal.pone.0271002
Autor
Cavalcante, Bruno Raphael Ribeiro
Freitas, Raíza Dias
Rocha, Leonardo de Oliveira Siquara da
Rocha, Gisele Vieira
Pachêco, Túlio Cosme de Carvalho
Ramos, Pablo Ivan Pereira
Rocha, Clarissa Araújo Gurgel
Resumen
Programa Nacional de Apoio à Atenção Oncológica (PRONON).
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
INOVA Fiocruz.
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).
Fundação Maria Emília.
Instituto Gonçalo Moniz, Fundação Oswaldo Cruz. Drug repurposing has been applied in the biomedical field to optimize the use of existing drugs, leading to a more efficient allocation of research resources. In oncology, this approach is particularly interesting, considering the high cost related to the discovery of new drugs with therapeutic potential. Computational methods have been applied to predict associations between drugs and their targets. However, drug repurposing has not always been promising and its efficiency has yet to be proven. Therefore, the present scoping review protocol was developed to screen the literature on how in silico strategies can be implemented in drug repurposing in oncology. The scoping review will be conducted according to the Arksey and O’Malley framework (2005) and the Joanna Briggs Institute recommendations. We will search the PubMed/MEDLINE, Embase, Scopus, and Web of Science databases, as well as the grey literature. We will include peer-reviewed research articles involving in silico strategies applied to drug repurposing in oncology, published between January 1, 2003, and December 31, 2021. Data will be charted and findings described according to review questions. We will report the scoping review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Review guidelines (PRISMA-ScR).